163 related articles for article (PubMed ID: 34880302)
1. Impact of macular fluid features on outcomes of anti-vascular endothelial growth factor treatment for type 3 macular neovascularization.
Yoon W; Yoon J; Na SK; Lee J; Kim J; Kim JW; Cho HJ
Sci Rep; 2021 Dec; 11(1):23643. PubMed ID: 34880302
[TBL] [Abstract][Full Text] [Related]
2. Analyses of the effects of persistent subretinal fluid on visual/anatomic outcomes according to the type of macular neovascularization during the relaxed treat-and-extend protocol in age-related macular degeneration patients.
Kim KT; Chae JB; Lee S; Seo EJ; Kim DY
BMC Ophthalmol; 2021 Aug; 21(1):294. PubMed ID: 34376158
[TBL] [Abstract][Full Text] [Related]
3. The association of exudation pattern with anatomical and functional outcomes in patients with Neovascular Age-Related Macular Degeneration.
Inan S; Polat O; Karadas M; Inan UU
Rom J Ophthalmol; 2019; 63(3):238-244. PubMed ID: 31687625
[No Abstract] [Full Text] [Related]
4. Correlation of 3-Dimensionally Quantified Intraretinal and Subretinal Fluid With Visual Acuity in Neovascular Age-Related Macular Degeneration.
Waldstein SM; Philip AM; Leitner R; Simader C; Langs G; Gerendas BS; Schmidt-Erfurth U
JAMA Ophthalmol; 2016 Feb; 134(2):182-90. PubMed ID: 26661463
[TBL] [Abstract][Full Text] [Related]
5. Difference Between the Incidence of Retinal Fluid Subtypes and Their Association with Visual Outcomes According to the Types of Macular Neovascularization in a Korean Population.
Kim JH; Kim JW; Kim CG
J Ocul Pharmacol Ther; 2022 Apr; 38(3):261-268. PubMed ID: 35119292
[No Abstract] [Full Text] [Related]
6. Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials.
Sharma S; Toth CA; Daniel E; Grunwald JE; Maguire MG; Ying GS; Huang J; Martin DF; Jaffe GJ;
Ophthalmology; 2016 Apr; 123(4):865-75. PubMed ID: 26783095
[TBL] [Abstract][Full Text] [Related]
7. Clinical characteristics and visual outcomes of non-resolving subretinal fluid in neovascular AMD despite continuous monthly anti-VEGF injections: a long-term follow-up.
Hosseini H; Rabina G; Pettenkofer M; Au A; Chehaibou I; Heilweil G; Weiner AJ; Ip M; Loewenstein A; Schwartz SD
Graefes Arch Clin Exp Ophthalmol; 2021 May; 259(5):1153-1160. PubMed ID: 33245430
[TBL] [Abstract][Full Text] [Related]
8. OCT Predictors of 3-Year Visual Outcome for Type 3 Macular Neovascularization.
Sacconi R; Forte P; Tombolini B; Grosso D; Fantaguzzi F; Pina A; Querques L; Bandello F; Querques G
Ophthalmol Retina; 2022 Jul; 6(7):586-594. PubMed ID: 35227948
[TBL] [Abstract][Full Text] [Related]
9. Neovascular age-related macular degeneration in which exudation predominantly occurs as a subretinal fluid during anti-vascular endothelial growth factor treatment.
Cho HJ; Song MY; Yoon W; Yoon J; Na SK; Lee J; Kim J; Kim JW
Sci Rep; 2022 Feb; 12(1):3167. PubMed ID: 35210516
[TBL] [Abstract][Full Text] [Related]
10. Role of intraretinal and subretinal fluid on clinical and anatomical outcomes in patients with neovascular age-related macular degeneration treated with bimonthly, treat-and-extend and as-needed ranibizumab in the In-Eye study.
Saenz-de-Viteri M; Recalde S; Fernandez-Robredo P; López Gálvez MI; Arias Barquet L; Figueroa MS; García-Arumí J; García-Layana A;
Acta Ophthalmol; 2021 Dec; 99(8):861-870. PubMed ID: 33720541
[TBL] [Abstract][Full Text] [Related]
11. Macular Morphology and Visual Acuity in Year Five of the Comparison of Age-related Macular Degeneration Treatments Trials.
Jaffe GJ; Ying GS; Toth CA; Daniel E; Grunwald JE; Martin DF; Maguire MG;
Ophthalmology; 2019 Feb; 126(2):252-260. PubMed ID: 30189282
[TBL] [Abstract][Full Text] [Related]
12. Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration.
Simader C; Ritter M; Bolz M; Deák GG; Mayr-Sponer U; Golbaz I; Kundi M; Schmidt-Erfurth UM
Ophthalmology; 2014 Jun; 121(6):1237-45. PubMed ID: 24684838
[TBL] [Abstract][Full Text] [Related]
13. Difference in characteristics and lesion reactivation between type 3 macular neovascularization with and without subretinal fluid at baseline.
Kim JH; Kim JW; Kim CG
Graefes Arch Clin Exp Ophthalmol; 2023 Feb; 261(2):401-408. PubMed ID: 36112220
[TBL] [Abstract][Full Text] [Related]
14. Variable response of subretinal hyperreflective material to anti-vascular endothelial growth factor classified with optical coherence tomography angiography.
Maruyama-Inoue M; Sato S; Yamane S; Kadonosono K
Graefes Arch Clin Exp Ophthalmol; 2018 Nov; 256(11):2089-2096. PubMed ID: 30173338
[TBL] [Abstract][Full Text] [Related]
15. Pilot study to evaluate the role of high-dose ranibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with persistent/recurrent macular fluid <30 days following treatment with intravitreal anti-VEGF therapy (the LAST Study).
Fung AT; Kumar N; Vance SK; Slakter JS; Klancnik JM; Spaide RS; Freund KB
Eye (Lond); 2012 Sep; 26(9):1181-7. PubMed ID: 22878451
[TBL] [Abstract][Full Text] [Related]
16. The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration--a phase IV randomised clinical trial with ranibizumab: the FLUID study.
Arnold JJ; Markey CM; Kurstjens NP; Guymer RH
BMC Ophthalmol; 2016 Mar; 16():31. PubMed ID: 27009515
[TBL] [Abstract][Full Text] [Related]
17. Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen: FLUID Study 24-Month Results.
Guymer RH; Markey CM; McAllister IL; Gillies MC; Hunyor AP; Arnold JJ;
Ophthalmology; 2019 May; 126(5):723-734. PubMed ID: 30502372
[TBL] [Abstract][Full Text] [Related]
18. Development of Intraretinal Fluid in Neovascular Age-Related Macular Degeneration During Anti-Vascular Endothelial Growth Factor Treatment.
Cho HJ; Yoon W; Yoon J; Na SK; Lee J; Kim J; Kim CG; Kim JW
Am J Ophthalmol; 2022 Feb; 234():6-14. PubMed ID: 34339661
[TBL] [Abstract][Full Text] [Related]
19. Polymorphisms in the APOE gene and the location of retinal fluid in eyes with neovascular age-related macular degeneration.
Wickremasinghe SS; Sandhu SS; Amirul-Islam FM; Abedi F; Richardson AJ; Baird PN; Guymer RH
Retina; 2014 Dec; 34(12):2367-75. PubMed ID: 25077528
[TBL] [Abstract][Full Text] [Related]
20. Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials.
Jaffe GJ; Martin DF; Toth CA; Daniel E; Maguire MG; Ying GS; Grunwald JE; Huang J;
Ophthalmology; 2013 Sep; 120(9):1860-70. PubMed ID: 23642377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
